Pernicious anemia (PA) is the final stage of autoimmune gastritis and characterized by vitamin B12 deficiency.1 Its definitive diagnosis is important because the patients need lifelong parenteral vitamin B12 treatment.2
PA is associated with two autoantibodies that can be used for diagnostic testing:1
The simultaneous determination of antibodies to parietal cells and those to intrinsic factor create a higher probability in the diagnosis of PA.1,2
With an exceptionally high clinical specificity of 99.4% and 89.9%, respectively, combined with a clinical sensitivity of 51.9% and 81.0%, respectively, EliA™ Intrinsic Factor test and EliA™ Parietal Cell test form the best-in-class, fully automated portfolio to aid in the diagnosis of PA.3
Combining the outstanding sensitivity and specificity of the EliA Intrinsic Factor and EliA Parietal Cell test increases the clinical sensitivity to 91.1% while maintaining specificity at 87%, helping you put the patient first by detecting more patients suffering from PA, sooner.3
EliA Intrinsic Factor test and EliA Parietal Cell test can be measured from one sample in one run and on the same fully automated Phadia™ Laboratory Systems.